Currently there is
no specific treatment for Ebola Hemorrhagic Fever.
Till date, only supportive care is available (intravenous fluids; blood and platelet transfusions), although upcoming human vaccine trials may be promising. The National Institutes of Health (USA) will begin a human vaccine trial in September 2014.
The prospects of transfusing blood or plasma from those patients who have recently recovered from Ebola virus infection seem promising. This could be an effective treatment as Ebola prophylaxis or for use in early onset of Ebola symptoms.
Use of an experimental compound, referred to as BCX4430, was reported in the journal Nature in April 2014. The compound, an RNA-dependent RNA polymerase inhibitor, has proven successful in a nonhuman primate model, whereby postexposure prophylaxis to BCX4430 prevented death in 17 of 18 macaques studied. No human trials have yet been reported.
Till date, only supportive care is available (intravenous fluids; blood and platelet transfusions), although upcoming human vaccine trials may be promising. The National Institutes of Health (USA) will begin a human vaccine trial in September 2014.
The prospects of transfusing blood or plasma from those patients who have recently recovered from Ebola virus infection seem promising. This could be an effective treatment as Ebola prophylaxis or for use in early onset of Ebola symptoms.
Use of an experimental compound, referred to as BCX4430, was reported in the journal Nature in April 2014. The compound, an RNA-dependent RNA polymerase inhibitor, has proven successful in a nonhuman primate model, whereby postexposure prophylaxis to BCX4430 prevented death in 17 of 18 macaques studied. No human trials have yet been reported.
No hay comentarios:
Publicar un comentario
Nota: solo los miembros de este blog pueden publicar comentarios.